Clinical Trials Logo

Cocaine Use Disorder clinical trials

View clinical trials related to Cocaine Use Disorder.

Filter by:

NCT ID: NCT06273540 Not yet recruiting - Clinical trials for Cocaine Use Disorder

Phase1, STP7 Cocaine Drug-Drug Interaction Study

Start date: March 1, 2024
Phase: Phase 1
Study type: Interventional

This is a double-blind, placebo-controlled, parallel group study to compare the effects of STP7 (mavoglurant) vs placebo control on i.v. cocaine's physiological and subjective effects in non-treatment seeking, cocaine-experienced males or females participants between 18 and 59 years of age. The primary objective of this study is to determine if there are clinically meaningful interactions between oral STP7 (mavoglurant) treatment concurrent with 20 and 40 mg i.v. cocaine infusions by measuring adverse events and cardiovascular responses including heart rate, blood pressure, and electrocardiogram (including corrected QT interval). The secondary objectives are: - To evaluate whether administration of STP7 (mavoglurant) alters the pharmacokinetics of cocaine and/or its major metabolite, benzoylecgonine. - To determine the pharmacokinetic of STP7 (mavoglurant) administered at a dose of 200 mg twice a day. - To evaluate whether STP7 (mavoglurant) treatment alters the subjective effects of cocaine measured by Visual Analog Scales (VAS) and Brief Substance Craving Scale (BSCS).

NCT ID: NCT06252623 Not yet recruiting - Clinical trials for Cocaine Use Disorder

Exenatide For Reducing the Reinforcing Effects of Cocaine

Start date: April 1, 2024
Phase: Phase 1
Study type: Interventional

This study will determine the safety and tolerability of exenatide (Bydureon®) as a pharmacotherapy for cocaine use disorder. An inpatient human laboratory study will be conducted in which the self-administration of cocaine, as well as the subjective and physiological effects of cocaine, are evaluated during maintenance on placebo and exenatide. Although exenatide (Bydureon) is approved by the Food and Drug Administration (FDA) for the treatment of type 2 diabetes, it has not been approved by the FDA to treat cocaine use; therefore, it is called an investigational drug.

NCT ID: NCT06125054 Recruiting - Cocaine Dependence Clinical Trials

Ketamine and Neurofeedback-Training: Effects on Neuroplasticity in Cocaine Addiction

Co-Boost
Start date: February 5, 2024
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to learn about the effects of the combination of ketamine and realtime functional magnetic resonance imaging (fMRI) neurofeedback training in individuals with cocaine use disorder. The main questions the investigators aim to answer are: - Can the investigators observe a positive, significant effect on percentage of cocaine use days of both interventions combined as well as stand alone interventions? - Is there a significant transfer effect of the neurofeedback training? - Is there a significant, ketamine-dependent change in glutamate levels in the nucleus accumbens? Participants will be given ketamine and a realtime fMRI neurofeedback training. Both interventions are placebo-controlled. The investigators will compare the four intervention groups to investigate the effects of the stand-alone effects of the intervention and the combination of it.

NCT ID: NCT06102434 Not yet recruiting - Clinical trials for Cocaine Use Disorder

Safety Profile of Psilocybin for Cocaine Use Disorder

Start date: February 2024
Phase: Early Phase 1
Study type: Interventional

The purpose of this study is to establish the safe administration of psilocybin in individuals with cocaine use disorder in terms of cardiovascular (e.g., heart rate) and subjective (e.g., mood) effects. The study's subject population consists of men and women between the ages of 21 and 55 from the Los Angeles area that meet criteria for cocaine use disorder and express an interest in ceasing cocaine use. 25 mg oral psilocybin will be administered to 10 individuals (separately) during a single laboratory visit. The laboratory visit will take place from 9 am until 3 pm within a comfortable, living room like environment. Within this study session room, participants will be accompanied by two clinicians. Participants will then consume the psilocybin capsule, and thereafter will be encouraged to lie down on a couch and introspect on the experience. At one-hour intervals following ingestion, participants will be tested briefly for changes in heart rate, blood pressure, and subjective effects. No blood draws, behavioral assessments, or neuroimaging is included in the study. Following the laboratory visit, investigators will check-in on participants remotely, after 48 hours, and 10, 50, and 90 days from the psilocybin session.

NCT ID: NCT06050304 Not yet recruiting - Clinical trials for Cocaine Use Disorder

CRACK-TARGET 1: ÉTUDE DESCRIPTIVE DE LA SENSIBILISATION COMPORTEMENTALE OBSERVÉE et ATTENTES

CRACK-TARGET
Start date: September 2023
Phase:
Study type: Observational

This research focuses on behavioral sensitization (BS) a specific behavioural disturbance in crack-cocaine addiction. The primary objective is to observe whether BS can be demonstrated in an ecological setting in crack dependent users by continuous actimetry for 3 weeks. It is planned to include 20 persons with a current crack-cocaine addiction with a preferential use of rapid administration route (intravenous or smoke), in a care institution: Fernand Widal Hospital. In the proposed research, the investigators will assess the movements of crack-cocaine dependent users in relation to consumption. They will have to wear continuously for 3 weeks an actimeter. They will also have 3 blood tests trying to identify biomarkers of BS.

NCT ID: NCT06025396 Completed - Healthy Volunteers Clinical Trials

Multiple Ascending Dose Study of TMP-301 in Healthy Subjects

Start date: January 6, 2023
Phase: Phase 1
Study type: Interventional

A PHASE 1, RANDOMIZED, PLACEBO CONTROLLED, MULTIPLE ASCENDING DOSE (MAD) STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF TMP-301 IN HEALTHY SUBJECTS.

NCT ID: NCT05986578 Not yet recruiting - Clinical trials for Cocaine Use Disorder

Identifying Electrophysiological Targets for Transcranial Magnetic Stimulation in Cocaine Use Disorder

Start date: December 1, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to assess effects of intermittent theta burst stimulation (iTBS) to left dorsolateral prefrontal cortex (dlPFC) and dorsomedial prefrontal cortex (dmPFC) compared to sham on electrophysiological indices of reward sensitivity and motivated attention in adults with cocaine use disorder.

NCT ID: NCT05978167 Recruiting - Clinical trials for Cocaine Use Disorder

Targeting Drug Memories With Methylphenidate

Start date: July 5, 2023
Phase: Early Phase 1
Study type: Interventional

This study aims to identify the neural, behavioral, and pharmacological mechanisms promoting diminished expression of drug-related memories in human drug addiction. In this fMRI study with a within-subjects placebo-controlled double-blind cross-over design, oral methylphenidate (20 mg) or placebo will be administered to individuals with cocaine use disorders (CUD) to peak during the retrieval of a drug-cue memory before extinction; in addition to fMRI activations, skin conductance responses (SCR, acquired simultaneously) will serve as the psychophysiological indicators of memory modification. Assessments of interference with the return of drug-cue memories via SCR and craving will be conducted the day following MRI. This pharmocologically-enhanced behavioral approach to decreasing drug memories and craving in iCUD could ultimately be used to develop effective cue-exposure therapies for drug addiction. Procedures include MRI, blood draw, questionnaires and interviews, skin conductance response measures, and behavioral tasks.

NCT ID: NCT05974202 Not yet recruiting - Cocaine Dependence Clinical Trials

rTMS and Cognitive-behavioral Therapy for Cocaine Use Disorder

Start date: June 15, 2024
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to compare the effects of active repetitive transcranial magnetic stimulation (rTMS) to sham (placebo) rTMS prior to cognitive-behavioral therapy (CBT) as a treatment for adults with cocaine use disorder. The main questions it aims to answer are: - Is rTMS safe and feasible as an augmentation for CBT for the treatment of cocaine use disorder? - What is the brain mechanism of rTMS? - Will active rTMS (compared to sham rTMS) followed by CBT help adults with cocaine use disorder achieve abstinence from cocaine? Participants will: - Have two brain MRI scans; - Undergo 3 weeks of daily rTMS (or sham) treatments (15 sessions), and; - Have 12 weeks of once-weekly cognitive-behavioral therapy for the treatment of cocaine use disorder. Researchers will compare active (real) rTMS to sham (placebo) rTMS. All participants will receive cognitive-behavioral therapy.

NCT ID: NCT05902819 Recruiting - Clinical trials for Post-traumatic Stress Disorder

Reconsolidation Blockade of Intrusive Trauma- and Cocaine-related Memories

Memocycline
Start date: May 10, 2023
Phase: N/A
Study type: Interventional

An investigation of the effect of matrix-metalloproteinase-(MMP)-9 inhibition with minocycline on the reconsolidation of trauma- or cocaine-related memories